RAN-QUINAPRIL TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE)

Предлага се от:

RANBAXY PHARMACEUTICALS CANADA INC.

АТС код:

C09AA06

INN (Международно Name):

QUINAPRIL

дозиране:

40MG

Лекарствена форма:

TABLET

Композиция:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40MG

Начин на приложение:

ORAL

Броя в опаковка:

30/1000

Вид предписание :

Prescription

Терапевтична област:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Каталог на резюме:

Active ingredient group (AIG) number: 0123206004; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2014-10-17

Данни за продукта

_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
RAN
™
-QUINAPRIL
QUINAPRIL TABLETS USP
(5 MG, 10 MG, 20 MG AND 40 MG OF QUINAPRIL AS QUINAPRIL HYDROCHLORIDE)
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
June 22, 2017
CONTROL NO. 206533
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
15
DOSAGE AND ADMINISTRATION
................................................................................
18
OVERDOSAGE
...................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION ANDPACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
24
PHARMACEUTICAL INFORMATION
......................